What biomarkers should I check before considering GHK-Cu
The confusion is understandable because NAD injections are sometimes offered by the same longevity or wellness clinics that provide peptide therapies
Zannad F, Stough WG, Lipicky RJ, Tamargo J, Bakris GL, Borer JS, Alonso Garca Mde L, Hadjadj S, Koenig W, Kupfer S, McCullough PA, Mosenzon O, Pocock S, Scheen AJ, Sourij H, Van der Schueren B, Stahre C, White WB, Calvo G
However: Larger meta-analyses show no significant increase in risk after adjusting for confounders [25] Incidence appears similar to other diabetes therapies [25] Much of the observed signal likely reflects: Baseline risk (obesity, T2DM) Secondary gallstone disease In summary, pancreatitis in GLP-1 users is a rare and possible complication, but current evidence does not support a substantial increase in risk directly related to GLP-1 agents
(This does not include cholecystectomy, or gallbladder removal.) Severe gastrointestinal disease, such as ulcerative colitis or gastroparesis